Nio Y, Ohgaki K, Tsuchitani T, Imai S, Shiraishi T, Tsubono M, Morimoto H, Tseng C C, Tobe T
Nihon Gan Chiryo Gakkai Shi. 1989 Aug 20;24(8):1607-15.
A streptococcal preparation, OK-432 at a dose of 5 KE was orally administered to the patients with gastric or colorectal cancer for 7 approximately 14 days before operation, and its immunomodulatory effects on peripheral blood lymphocytes (PBL), regional lymph node lymphocytes (RLNL) and tumor infiltrating lymphocytes (TIL) were assessed. OK-432 treated group included 5 gastric and 6 colorectal cancers, and control group included 6 gastric and 8 colorectal cancers. After oral administration of OK-432 the proportion of Leu 7+ and Leu 11+ cells in PBL increased, and NK cell activity of PBL also was augmented. The proportion of OKT8+ cells increased in PBL and those of OKT3+ cells and OKT8+ cells decreased in RLNL after oral administration of OK-432. The responsiveness of TIL to autologous tumor extracts in the presence of interleukin-2 was enhanced in oral OK-432 group. These results indicate that oral OK-432 affects on NK and T cells and augments the antitumor immunity of the patients with gastrointestinal cancer.
将剂量为5KE的链球菌制剂OK-432口服给予胃癌或结直肠癌患者，在手术前约7至14天给药，评估其对外周血淋巴细胞（PBL）、区域淋巴结淋巴细胞（RLNL）和肿瘤浸润淋巴细胞（TIL）的免疫调节作用。OK-432治疗组包括5例胃癌和6例结直肠癌患者，对照组包括6例胃癌和8例结直肠癌患者。口服OK-432后，PBL中Leu 7+和Leu 11+细胞的比例增加，PBL的NK细胞活性也增强。口服OK-432后，PBL中OKT8+细胞的比例增加，RLNL中OKT3+细胞和OKT8+细胞的比例降低。口服OK-432组中，在白细胞介素-2存在的情况下，TIL对自体肿瘤提取物的反应性增强。这些结果表明，口服OK-432对NK细胞和T细胞有影响，并增强了胃肠道癌患者的抗肿瘤免疫力。
